Anzeige
Mehr »
Login
Montag, 31.03.2025 Börsentäglich über 12.000 News von 695 internationalen Medien

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3C2EY | ISIN: US04635X1028 | Ticker-Symbol: 2090
NASDAQ
31.03.25
21:46 Uhr
5,330 US-Dollar
-0,510
-8,73 %
Branche
Pharma
Aktienmarkt
NASDAQ Biotech
1-Jahres-Chart
ASTRIA THERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
ASTRIA THERAPEUTICS INC 5-Tage-Chart
RealtimeGeldBriefZeit
4,8205,05022:00

Aktuelle News zur ASTRIA THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
11.03.Astria Therapeutics, Inc. - 10-K, Annual Report3
11.03.Astria TherapeuticS GAAP EPS of -$1.68 beats by $0.013
11.03.Astria Therapeutics, Inc. - 8-K, Current Report1
28.02.Astria Therapeutics, Inc.: Astria Therapeutics beginnt Phase-3-Zulassungsstudie ALPHA-ORBIT zu Navenibart bei hereditärem Angioödem295-- Studie zum Nachweis der Wirksamkeit und Sicherheit der Verabreichung alle 3 und alle 6 Monate in einem 6-monatigen Behandlungszeitraum -- Astria Therapeutics, Inc. (Nasdaq: ATXS), ein biopharmazeutisches...
► Artikel lesen
18.02.JMP SECURITIES REITERATES ASTRIA THERAPEUTICS OUTPERFORM RATING18
13.01.Astria Therapeutics, Inc. - 8-K, Current Report9
ASTRIA THERAPEUTICS Aktie jetzt für 0€ handeln
13.01.Astria Therapeutics, Inc. (NASDAQ:ATXS) Given Average Rating of "Buy" by Brokerages13
19.12.24Astria Therapeutics, Inc. - 8-K, Current Report6
10.12.24FDA genehmigt klinische Studie für neues AD-Medikament von Astria Therapeutics21
10.12.24FDA clears Astria Therapeutics' new AD drug for trial2
14.11.24Astria TherapeuticS GAAP EPS of -$0.42 in-line9
13.11.24Astria Therapeutics Reports Third Quarter 2024 Financial Results and Provides a Corporate Update202BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today reported...
► Artikel lesen
13.11.24Astria Therapeutics, Inc. - 10-Q, Quarterly Report-
13.11.24Astria Therapeutics, Inc.: Astria Therapeutics to Present at Upcoming Jefferies London Healthcare Conference248Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced that Jill C. Milne, Ph.D....
► Artikel lesen
24.10.24Astria Therapeutics (NASDAQ:ATXS) Shares Up 6.8% - Should You Buy?6
17.10.24Astria Therapeutics' navenibart gains orphan medicinal status from EC8
16.10.24Astria Therapeutics gains orphan drug status in EU for HAE treatment8
27.09.24Astria Therapeutics, Inc.: Astria Therapeutics to Present at Upcoming Global Angioedema Forum462Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced that leading HAE experts...
► Artikel lesen
19.09.24Astria Therapeutics, Inc.: Astria Therapeutics to Present at Upcoming European Academy of Dermatology and Venerology Congress359Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced that it will present initial...
► Artikel lesen
30.08.24Astria Therapeutics, Inc.: Astria Therapeutics to Present at Upcoming Bradykinin Symposium429Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced that it will present two...
► Artikel lesen
Seite:  Weiter >>
23 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1